Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex

Epilepsia

Volumn 56, Issue 7, 2015, Pages 1088-1097

  Rensing, Nicholas ^a   Han, Lirong ^a   Wong, Michael ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epilepsy; Mechanistic target of rapamycin; Mice; Rapamycin; Seizure

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEMBRANE PROTEIN; PROTEIN S6; RAPAMYCIN; TSC1 PROTEIN; UNCLASSIFIED DRUG; ANTICONVULSIVE AGENT; MTOR PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

ALEXANDER DISEASE; ANIMAL CELL; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; EPILEPSY; EPILEPTOGENESIS; FEMALE; GENE EXPRESSION; GLIA CELL; HISTOPATHOLOGY; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEIZURE; TREATMENT DURATION; TUBEROUS SCLEROSIS; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DOSE RESPONSE; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MICE; MICE, KNOCKOUT; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; TUBEROUS SCLEROSIS;

EID: 84936847547     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.13031     Document Type: Article

References (24)

1. Wong M,. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies. Epilepsia 2010; 51: 27-36.
2. Zeng LH, Xu L, Gutmann DH, et al., Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008; 63: 444-453.
3. Meikle L, Pollizzi K, Egnor A, et al., Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 2008; 28: 5422-5432.
4. Goto J, Talos DM, Klein P, et al., Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex. Proc Natl Acad Sci U S A 2011; 108: E1070-1079.
5. Zeng LH, Rensing NR, Zhang B, et al., Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum Mol Genet 2011; 20: 445-454.
6. Anderl S, Freeland M, Kwiatkowski DJ, et al., Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex. Hum Mol Gen 2011; 20: 4597-4604.
7. Carson RP, Van Nielen DL, Winzenburger PA, et al., Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin. Neurobiol Dis 2012; 45: 369-380.
8. Krueger DA, Wilfong AA, Holland-Bouley K, et al., Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013; 74: 679-687.
9. Uhlmann EJ, Wong M, Baldwin RL, et al., Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol 2002; 52: 285-296.
10. Zeng LH, Bero AW, Zhang B, Holtzman DH, Wong M,. Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of Tuberous Sclerosis Complex. Neurobiol Dis 2010; 37: 764-771.
11. Temkin NR,. Preventing and treating posttraumatic seizures: the human experience. Epilepsia 2009; 50 (Suppl. 2): 10-13.
12. Wong M,. A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials. Expert Rev Neurotherap 2013; 13: 657-669.
13. Daoud D, Scheld HH, Speckmann EJ, et al., Rapamycin: brain excitability studied in vitro. Epilepsia 2007; 48: 834-836.
14. Ruegg S, Baybis M, Juul H, et al., Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons. Epilepsy Res 2007; 77: 85-92.
15. Hartman AL, Santos P, Dolce A, et al., The mTOR inhibitor rapamycin has limited acute anticonvulsant effects in mice. PloS One 2012; 7: e45156.
16. Chachua T, Poon KL, Yum MS, et al., Rapamycin has age-, treatment paradigm-, and model-specific anticonvulsant effects and modulates neuropeptide Y expression in rats. Epilepsia 2012; 53: 2015-2025.
17. Huang X, McMahon J, Yang J, et al., Rapamycin down-regulates KCC2 expression and increases seizure susceptibility to convulsants in immature rats. Neurosci 2012; 219: 33-47.
18. Datta AN, Hahn CD, Sahin M,. Clinical presentation and diagnosis of tuberous sclerosis complex in infancy. J Child Neurol 2008; 23: 268-273.
19. Chu-Shore CJ, Major P, Camposano S, et al., The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2010; 51: 1236-1241.
20. Pallet N, Legendre C,. Adverse events associated with mTOR inhibitors. Expert Opinion in Drug Safety 2013; 12: 177-186.
21. Escolar DM, Hache LP, Clemens PR, et al., Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 2011; 77: 444-452.
22. Boulay A, Zumstein-Mecker S, Stephan C, et al., Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004; 64: 252-261.
23. Woodrum C, Nobil A, Dabora SL,. Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. J Translational Med 2010; 8: 14.
24. Sunnen CN, Brewster AL, Lugo JN, et al., Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice. Epilepsia 2011; 52: 2065-2075.